Biomarker-Based Treatment Selection in Non-Small Cell Lung Cancer

Patients with non–small cell lung cancer must be tested for biomarkers. Currently, treatments directed against EGFR, ALK, and ROS1 mutations are standard of care. A number of emerging new targets and treatments are on the horizon.

http://ift.tt/2qs1UOA